ANI Pharmaceuticals announced that it received U.S. FDA approval for the Abbreviated New Drug Application for Levocarnitine Tablets USP, 330 mg. ANI’s Levocarnitine Tablets are the generic version of the Reference Listed Drug Carnitor. The current annual U.S. market for Levocarnitine Tablets is approximately $10M, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANIP:
